移动式高分辨率PET/CT扫描仪用于手术标本的可行性研究:探索临床应用与实践考量
本研究在12个月内评估AURA 10移动PET/CT相机用于术中切除标本成像的可行性,涉及32台手术,覆盖甲状腺癌、尿路上皮癌、肾细胞癌、前列腺癌、乳腺癌、皮肤癌、淋巴结或骨活检及甲状旁腺腺瘤。术中PET/CT成像在(旁)甲状腺、泌尿外科手术和肿瘤学检查中显示出附加价值,以低放射性活度获得高质量图像并实现安全实施。
要点
- 在32台手术中测试了术中移动PET/CT对切除标本的成像,覆盖甲状腺癌、泌尿系统肿瘤、乳腺癌、皮肤癌、前列腺癌及甲状旁腺腺瘤等。
- 术者在标本扫描后12分钟可查看图像,标本PET/CT图像与病理结果进行了对照。
核心结论
- 在本院开展的术中手术标本PET/CT成像总体体验是有前景的,在(旁)甲状腺、泌尿外科手术和肿瘤学检查中具有附加价值。
- 以低放射性活度示踪剂即可获得高质量图像,使安全实施成为可能。
研究设计与样本
- 研究者发起的12个月评估研究,评估AURA 10 PET/CT相机(XEOS Medical,比利时)。
- 根据肿瘤类型,在肿瘤切除前60-90分钟静脉注射[18F]FDG、[18F]JK-PSMA-7、[18F]PSMA-1007或[18F]Choline。
- 组织在移动PET/CT设备中扫描,12分钟后外科医生可查看图像,标本PET/CT图像与病理结果对照,全程监测患者周围剂量率。
主要发现
- 该技术在32台手术中进行了测试:甲状腺癌(n=5)、移行细胞癌(n=2)、肾细胞癌(n=1)、前列腺癌(n=5)、乳腺癌(n=7)、皮肤癌(n=3)、肿瘤学检查的淋巴结或骨活检(n=6)及甲状旁腺腺瘤(n=3)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this trial we explore potential indications of an intra-operative mobile PET/CT camera. The tested device is designed to acquire high quality images of resected tissue specimens from patients who were administered a PET-tracer, shortly before resection. Besides clinical experiences, we will also comment on the practical aspects of the implementation of a safe workflow for intra-operative PET/CT-imaging. METHODS: This investigator driven study involved a 12-month evaluation of the AURA 10 PET/CT camera (XEOS Medical, Belgium). Depending on the tumour type, [18F]FDG, [18F]JK-PSMA-7, [18F]PSMA-1007 or [18F]Choline was injected intravenously 60-90 min prior to the removal of the tumour. The tissue was scanned in the mobile PET/CT-device and 12 min later the surgeon could review the images. Specimen PET/CT-images were confronted with pathology findings. Dose rates were monitored around the patient throughout the procedure. RESULTS: The technique was tested in 32 surgeries for thyroid carcinomas (n = 5), transitional cell carcinomas (n = 2,) renal cell carcinoma (n = 1), prostate cancer (n = 5), breast carcinoma (n = 7), skin cancer (n = 3), nodal or bone biopsy for oncology work up (n = 6) and parathyroid adenoma (n = 3). Normalized to an injected activity of 1 MBq/kg the estimated median absorbed doses per procedure were 15.6 µSv (range 0,7-140,8) and 14,1 µSv (0,5-46,2) for respectively the surgeons and instrumenting nurses. CONCLUSION: The overall experience of intra-operative PET/CT-imaging of surgical specimens was promising in our hospital, with particular added value in case of (para)thyroid, urological surgeries, and oncological work-ups. High quality images were obtained with low activity of tracers, enabling a safe implementation. TRIAL REGISTRATION NUMBER (BELGIUM): BUN: B0172022000009 (NCT retrospectively submitted).
引用
- Lambert B, Vergucht V, Dekeyser S, et al. Feasibility study on the implementation of a mobile high-resolution PET/CT scanner for surgical specimens: exploring clinical applications and practical considerations. Eur J Nucl Med Mol Imaging. 2025. PMID: 39976699. doi:10.1007/s00259-025-07143-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。